Ultimately, this review challenges the general strategy that the skin wound healing (Seiwerth et al., 1997
GHK-Cu is often referred to as the Glow Peptide because it signals your body to naturally increase collagen and elastin production
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Commercial payers establish their own fee schedules, which often exceed Medicare reimbursement rates for CPT code 20550
Yet, amidst the chatter, it's not uncommon to find a haze of confusion
Because GHK-Cu stimulates the skin's own collagen-producing machinery rather than temporarily plumping the surface, the firmness improvement is structural it's still there months later, not gone the moment a filler effect wears off